Prior human endemic coronavirus exposure does not affect humoral responses to SARS-CoV-2 protein vaccines.

IF 6.9 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2025-07-13 DOI:10.1038/s41541-025-01203-z

Guy de Bruyn, Haritha Adhikarla, Caroline K Brackett, Yichen Jia, Premkumar Lakshmanane, Sarah V Mudrak, Sheetal Sawant, Donghui Zhang, Roman M Chicz, Saranya Sridhar, Georgia D Tomaras, Kelly E Seaton

引用次数: 0

Abstract

We included measurement of pre-existing immunity to human endemic coronaviruses (HCoV) in a Phase I/II study of SARS-CoV-2 spike protein vaccine candidates. A Binding Antibody Multiplex Assay measured HCoV-specific IgG to the receptor binding domain or full-length spike of human coronaviruses HKU1, 229E, NL63, and OC43. We found no evidence for the impact of HCoV antibodies on neutralizing and binding antibody responses to the candidate SARS-CoV-2 vaccines.

查看原文本刊更多论文

先前的人类地方性冠状病毒暴露不影响对SARS-CoV-2蛋白疫苗的体液反应。

在SARS-CoV-2刺突蛋白候选疫苗的I/II期研究中，我们纳入了对人类地方性冠状病毒（HCoV）预先免疫的测量。结合抗体多重试验测定hcov特异性IgG对人冠状病毒HKU1、229E、NL63和OC43的受体结合域或全长刺突的影响。我们没有发现HCoV抗体对候选SARS-CoV-2疫苗的中和和结合抗体反应有影响的证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.